Michael W Griffith

US Patent:

20100316625, Dec 16, 2010

Filed:

Dec 16, 2008

Appl. No.:

12/744017

Inventors:

Samia Mankarious - Costa Mesa CA, US
Michael J. Griffith - San Juan Capistrano CA, US

Assignee:

Inspiration Biopharmaceuticals, Inc. - Laguna Niguel

International Classification:

A61K 38/48
A61P 7/04

US Classification:

424 9464

Abstract:

Methods of preparing lyophilized preparations of Factor IX which preserve more than 90% of the calcium binding property of Factor IX are disclosed. Factor IX formulated with trehalose shows a superior stability profile after 12 weeks storage at 25 C./60% relative humidity (RH) and 40 C./75% RH relative to Factor IX formulated without trehalose. The data suggest that the inclusion of trehalose in the formulation could allow for temperature excursions or even long-term room temperature storage of a Factor IX lyophilized product. The formulations tested contained 10 mM histidine pH 6.8, 3% mannitol, 66 mM sodium chloride, 0.0075% Polysorbate 80, with and without 1% trehalose. Upon storage at 40 C./75% RH or 25 C./60% RH over 12 weeks the trehalose-containing formulation was comparable to product stored at 2-8 C. while the formulation without trehalose was found to undergo significant aggregation and loss of activity. The two formulations demonstrated comparable stability over 26 weeks of real time storage at −20 C. and 2-8 C.

US Patent:

54709547, Nov 28, 1995

Filed:

Oct 21, 1993

Appl. No.:

8/140695

Inventors:

Gerard G. Neslund - Diamond Bar CA
Michael J. Griffith - Claremont CA

Assignee:

Baxter International Inc. - Deerfield IL

International Classification:

A61K 3516
C07K 118
C07K 122
C07K 14755

US Classification:

530383

Abstract:

A process for purifying Factor VIII:C comprising contacting an immobilized antibody specifically binding a Factor VIII:C with Factor VIII: C, desorbing Factor VIII:C from the antibody which had adsorbed it, eluting Factor VIII:C from the presence of the antibody, passing the eluted Factor VIII:C through an affinity region capable of binding the Factor VIII:C, binding the Factor VIII:C in the affinity region and passing contaminants through said region, and eluting the purified Factor VIII:C.

US Patent:

55030149, Apr 2, 1996

Filed:

Jul 28, 1994

Appl. No.:

8/281954

Inventors:

Michael J. Griffith - Needville TX

Assignee:

Schlumberger Technology Corporation - Houston TX

International Classification:

F21B 4300
F21B 2100

US Classification:

73155

Abstract:

A new drill stem test apparatus and corresponding method includes a dual coaxial coiled tubing adapted to be disposed in the wellbore. The dual coaxial coiled tubing includes an inner coiled tubing, and an outer coiled tubing surrounding and enclosing the inner coiled tubing and forming an annular space which is located between the inner coiled tubing and the outer coiled tubing. The annular space is adapted to contain a pressurized kill fluid. A first end of the outer coiled tubing is sealed by a sealing element to a first end of the inner coiled tubing, the end of the inner coiled tubing extending beyond the sealing element and adapted to receive a formation fluid. The first ends of the inner and outer coiled tubing are disposed in a wellbore. A second end of the inner and outer coiled tubing is wound onto a coiled tubing reel and is connected to a kill fluid valve and a formation fluid valve. When the kill fluid valve opens while the formation fluid valve is closed, a pressurized kill fluid fills and pressurizes the annular space between the inner and outer coiled tubing.

US Patent:

53546822, Oct 11, 1994

Filed:

Feb 24, 1993

Appl. No.:

8/023143

Inventors:

Henry S. Kingdon - Pasadena CA
Michael J. Griffith - Walnut CA
Joyce Lawrence - Claremont CA
Roger L. Lundblad - Chapel Hill NC

Assignee:

Baxter International Inc. - Deerfield IL

International Classification:

C12N 974
A61K 3514
A61K 37475

US Classification:

435214

Abstract:

A purified therapeutic grade thrombin is described which is essentially free of lipid envelope viruses, has a specific activity of about 2200 NIH units per milligram of protein to about 3200 NIH units per milligram of protein, is essentially homogeneous and may be produced on a commercial-scale. The thrombin is acceptable from human administration.

US Patent:

53618394, Nov 8, 1994

Filed:

Mar 24, 1993

Appl. No.:

8/036616

Inventors:

Michael J. Griffith - Needville TX
Ervin Randermann - Beasley TX

Assignee:

Schlumberger Technology Corporation - Houston TX

International Classification:

E21B 4908

US Classification:

166264

Abstract:

A formation fluid sampler adapted to be disposed in a wellbore includes a full bore and an outer housing. The outer housing includes an annular sample chamber having a first port disposed on one side of the chamber and a second port disposed on the other side of the chamber. The annular sample chamber further includes a fluid sample parameter transducer adapted for measuring a parameter of the fluid sample trapped in the annular sample chamber, and an EPROM memory for instantly storing the parameter measured by the transducer when the sample was initially taken by the sampler. The sampler also includes a piston disposed within the outer housing and adapted to move axially in the sampler in response to an annulus pressure around the sampler. The piston defines the full bore of the sampler and includes a first port adapted to move into congruence with the first port of the outer housing and a second port adapted to move into congruence with the second port of the outer housing in response to the axial movement of the piston. When the ports are congruent, one side of the annular sample chamber fluidly communicates with the full bore of the sampler and the other side of the annular sample chamber fluidly communicates with the full bore of the sampler.